株式会社かけはし、シリーズD資金調達ラウンドで140億円を調達

株式会社カケハシ当社は、ゴールドマン・サックス証券をリードインベスターとする総額約140億円のシリーズDラウンド（第三者割当増資、既存株主による株式譲渡、ベンチャーデット、ローン）の契約を締結いたしましたので、お知らせいたします。

With this funding, we will further deepen our collaboration with a wide range of players, and actively invest in M&A, new technologies, and human resources with a view to promoting these businesses. We will accelerate the expansion of our platform by strengthening our organizational foundation and expanding our products, and aim to solve Japan’s medical issues through the promotion of next-generation healthcare.

With the mission of “Making the Japanese medical experience flexible,” we have been promoting our business together with medical professionals and partner companies, aiming to create an ecosystem that will serve as the foundation for tomorrow’s healthcare.

- 広告

こちらもお読みください： BONX WORK、アイホンのVi-nurseシステムと統合

We develop and provide multiple products for pharmacies, including “Musubi,” a cloud-based electronic medical history and medication instruction tool launched in 2017, and the group as a whole covers more than 20% of pharmacies in Japan, more than 14,000 stores nationwide. ‍It has become the medical platform service of choice to promote the “next-generation of pharmacies,” which is being called into question in recent years due to the revision of the Pharmaceutical and Medical Device Act and the revision of medical treatment fees, and we have received many examples of strengthening the relationship between patients and pharmacists, improving medication adherence, and improving pharmacy management. Most recently, we have been selected for the Ministry of Economy, Trade and Industry’s “Demonstration Research Project for Promoting the Use of PHR in Medical Institutions,” and have been steadily achieving results in both technical research and social implementation, such as joint research with medical institutions and universities.

今後も、薬局向けサービスの拡充に加え、患者様への介入・フォローアップによる治療・医薬品価値の最大化、医療用医薬品にとどまらない生活者の健康増進・QOL最大化に向けたPHRの活用、薬局・卸・製薬メーカー等との連携による医薬品流通の最適化・安定供給など、薬局とともに医薬品・医療業界全体に視野を広げ、ヘルスケアの再発明による医療課題の解決に取り組んでまいります。こうした幅広い連携を実現するため、M&Aや新技術への投資を積極的に行い、課題解決のスピードをさらに加速させていきます。

ソース PRタイムズ